Know Labs Presents at Third Annual Bernstein CGM Disruptors Conference, Details Significant Progress During the Past Year
31 Octobre 2023 - 2:00PM
Business Wire
Know Labs, Inc. (NYSE American: KNW), an emerging developer of
non-invasive medical diagnostic technology, will present at the
third annual Bernstein CGM Disruptors Conference on Thursday,
November 2, 2023. Presenters and institutional investors from
across the globe will gather virtually to discuss the latest
developments in continuous glucose monitoring (CGM) technology.
Pete Conley, Chief Financial Officer, and Senior Vice President
of Intellectual Property (IP) at Know Labs, will provide an update
on the company’s progress over the past year. Highlights include a
significant expansion of the company’s IP leadership in the
non-invasive blood glucose monitoring category, with more than 246
patents issued, pending, and in process (a 176 percent increase
year-over-year); the publication of several peer-reviewed reports
on its clinical results; and the completed production of its
Generation 1 working prototype.
Mr. Conley will also provide development updates for the
company’s diagnostic technology platform and the path to bringing
the first FDA-cleared non-invasive blood glucose monitor to the
marketplace.
Throughout the year, Know Labs has remained focused on
refinement of their prototype device and its algorithms, as well as
external validation of the technology with its growing body of
peer-reviewed evidence, which can be found at
www.knowlabs.co/research-and-validation.
Interested parties can view Know Labs’ Bernstein CGM Disruptors
Conference presentation on the company website. Investor
information can also be found at www.knowlabs.co/investors. For
more information on Know Labs, visit www.knowlabs.co.
About Know Labs, Inc. Know Labs, Inc. is a public company
whose shares trade on the NYSE American Exchange under the stock
symbol “KNW.” The Company’s platform technology uses spectroscopy
to direct electromagnetic energy through a substance or material to
capture a unique molecular signature. The technology can be
integrated into a variety of wearable, mobile or bench-top form
factors. This patented and patent-pending technology makes it
possible to effectively identify and monitor analytes that could
only previously be performed by invasive and/or expensive and
time-consuming lab-based tests. The first application of the
technology will be in a product marketed as a non-invasive glucose
monitor. The device will provide the user with accessible and
affordable real-time information on blood glucose levels. This
product will require U.S. Food and Drug Administration clearance
prior to its introduction to the market.
Safe Harbor Statement This release contains statements
that constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These statements
appear in a number of places in this release and include all
statements that are not statements of historical fact regarding the
intent, belief or current expectations of Know Labs, Inc., its
directors or its officers with respect to, among other things: (i)
financing plans; (ii) trends affecting its financial condition or
results of operations; (iii) growth strategy and operating
strategy; and (iv) performance of products. You can identify these
statements by the use of the words “may,” “will,” “could,”
“should,” “would,” “plans,” “expects,” “anticipates,” “continue,”
“estimate,” “project,” “intend,” “likely,” “forecast,” “probable,”
“potential,” and similar expressions and variations thereof are
intended to identify forward-looking statements. Investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties, many of which are beyond Know Labs, Inc.’s ability
to control, and actual results may differ materially from those
projected in the forward-looking statements as a result of various
factors. These risks and uncertainties also include such additional
risk factors as are discussed in the Company’s filings with the
U.S. Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended September 30, 2022,
Forms 10-Q and 8-K, and in other filings we make with the
Securities and Exchange Commission from time to time. These
documents are available on the SEC Filings section of the Investor
Relations section of our website at www.knowlabs.co. The Company
cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
The Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on
which such statement is made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031068693/en/
For Know Labs Media Inquiries: Matter Health Abby Mayo
Knowlabs@matternow.com Ph. (617) 272-0592
Know Labs, Inc.: Jordyn Hujar jordyn@knowlabs.co Ph.
(206) 629-6414
Know Labs (AMEX:KNW)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Know Labs (AMEX:KNW)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024